Sacubitril/valsartan ameliorates cardiac hypertrophy and preserves diastolic function in cardiac pressure overload-Reference-Cited by-同舟云学术

Sacubitril/valsartan ameliorates cardiac hypertrophy and preserves diastolic function in cardiac pressure overload

Published:2021-01-26 Issue:2 Volume:8 Page:918-927
ISSN:2055-5822
Container-title:ESC Heart Failure
language:en
Short-container-title:ESC Heart Failure

Author:

Nordén Einar Sjaastad¹²³⁴,Bendiksen Bård Andre¹²³⁴,Andresen Henriette¹,Bergo Kaja Knudsen¹³⁴,Espe Emil Knut¹²³⁴,Hasic Almira¹³⁴,Hauge‐Iversen Ida Marie¹³⁴,Veras Ioanni¹³⁴,Hussain Rizwan I.⁵,Sjaastad Ivar¹²³⁴,Christensen Geir¹³⁴,Cataliotti Alessandro¹³⁴

Affiliation:

1. Institute for Experimental Medical Research Oslo University Hospital and University of Oslo Oslo Norway

2. Department for Health Sciences Bjørknes University College Oslo Norway

3. KG Jebsen Center for Cardiac Research University of Oslo Oslo Norway

4. Center for Heart Failure Research Oslo University Hospital Oslo Norway

5. Novartis AG Basel Switzerland

Publisher

Wiley

Subject

Cardiology and Cardiovascular Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ehf2.13177

Reference35 articles.

1. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

2. Administration USFaD.FDA approves new drug to treat heart failure.http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm453845.htm2015[cited 2016 02/27]; Available from:http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm453845.htmAccessed 27 February 2016.

3. Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure

4. Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction

5. Epidemiology and risk profile of heart failure

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effects of sacubitril-valsartan on aging-related cardiac dysfunction;European Journal of Pharmacology;2024-09

2. Sacubitril/valsartan protective effect on induced intestinal ischemia/reperfusion injury via immune modulation of IL6/STAT1 pathway;Journal of Pharmacy and Pharmacology;2024-03-27

3. Hitting the Target! Challenges and Opportunities for TGF-β Inhibition for the Treatment of Cardiac fibrosis;Pharmaceuticals;2024-02-20

4. Treatment with Sacubitril/Valsartan Effectively Manages Hypertension and Ameliorates Left Ventricular Hypertrophy in Hemodialysis Patients;Blood Purification;2024

5. Muscone inhibits angiotensin II–induced cardiac hypertrophy through the STAT3, MAPK and TGF-β/SMAD signaling pathways;Molecular Biology Reports;2023-12-29